GLRA
ACAD icon

Gerald L. Ray & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Gerald L. Ray & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$7.51M Buy
199,260
+2,480
+1% +$80.7K 0.94% 24
2017
Q2 		$5.49M Buy
196,780
+13,130
+7% +$391K 0.71% 34
2017
Q1 		$6.31M Buy
183,650
+3,370
+2% +$119K 0.86% 29
2016
Q4 		$5.2M Buy
180,280
+14,990
+9% +$397K 0.75% 32
2016
Q3 		$5.26M Buy
165,290
+5,700
+4% +$193K 0.79% 32
2016
Q2 		$5.18M Buy
159,590
+4,400
+3% +$147K 0.83% 31
2016
Q1 		$4.34M Buy
155,190
+50,540
+48% +$1.1M 0.7% 38
2015
Q4 		$3.73M Buy
104,650
+2,140
+2% +$75.4K 0.59% 43
2015
Q3 		$3.39M Buy
102,510
+3,560
+4% +$148K 0.57% 47
2015
Q2 		$4.14M Sell
98,950
-800
-0.8% -$31K 0.63% 44
2015
Q1 		$3.25M Buy
99,750
+1,500
+2% +$51.6K 0.49% 48
2014
Q4 		$3.12M Buy
98,250
+450
+0.5% +$12.8K 0.48% 50
2014
Q3 		$2.42M Buy
97,800
+8,000
+9% +$187K 0.39% 66
2014
Q2 		$2.03M Buy
89,800
+11,450
+15% +$239K 0.35% 77
2014
Q1 		$1.91M Buy
78,350
+14,800
+23% +$374K 0.35% 75
2013
Q4 		$1.59M Buy
63,550
+17,000
+37% +$401K 0.3% 82
2013
Q3 		$1.28M Buy
+46,550
New +$973K 0.26% 89

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Gerald L. Ray & Associates's ACAD Position: Q3 2017 in Review

Gerald L. Ray & Associates increased its Acadia Pharmaceuticals (ACAD) stake by 1.3% in Q3 2017, buying an estimated $80.7K and bringing the position to 199,260 shares worth $7.51M. The position accounts for 0.94% of the portfolio, ranked #24.

Gerald L. Ray & Associates first reported a position in ACAD in Q3 2013 and has held it in 17 quarters since. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

  • Gerald L. Ray & Associates held 199,260 shares of Acadia Pharmaceuticals worth $7.51M as of Q3 2017.
  • Gerald L. Ray & Associates bought 2,480 Acadia Pharmaceuticals shares in Q3 2017, an estimated $80.7K.
  • Acadia Pharmaceuticals made up 0.94% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #24 holding.
  • Gerald L. Ray & Associates first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 17 quarters since.
  • 212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.